Insmed (NASDAQ:INSM) Price Target Raised to $68.00

Insmed (NASDAQ:INSM – Free Report) had its price objective upped by Truist Financial from $48.00 to $68.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. INSM has been the subject of several other research reports. Mizuho boosted their price target on shares of […]

Related Keywords

United States ,America ,William Lewis ,Sara Bonstein ,Jpmorgan Chase Co ,International Assets Investment Management ,Entrypoint Capital ,Fidelis Capital Partners ,Insmed Incorporated ,Barclays ,Nasdaq ,Headlands Technologies ,Free Report ,Truist Financial ,Moderate Buy ,Stock Down ,Get Free Report ,Assets Investment Management ,Point Capital ,Capital Partners ,Insmed Daily ,